Evaluating the Impact of Intensifying Treatment from Human to Analogue Insulin on Glycaemic Control and Insulin Expenditure in Patients with Type 2 Diabetes: A Retrospective Cohort Study

Overview

Journal Malays J Med Sci

Specialty General Medicine

Date 2024 May 2

PMID 38694591

Authors

Siti Aisyah Hussin

Nur Aimi Mohamad

Mohd Khairi Othman

Wan Mohd Izani Wan Mohamed

Affiliations

Soon will be listed here.

Abstract

Background: Achieving good glycaemic control is essential to reducing the risk of diabetes complications. Insulin is the most effective therapy for achieving good glycaemic control; however, it is associated with a higher risk of hypoglycaemia, especially with human insulin. This study aimed to evaluate the efficacy of intensification from human to analogue insulin and its added cost.

Methods: This retrospective study was conducted at the Hospital Universiti Sains Malaysia (HUSM). Patients with type 2 diabetes mellitus (T2DM) who underwent intensification for at least 3 months from human to analogue insulin were included in this study. The patients' medical records, haemoglobin A1c (Hba1c) and fasting blood sugar (FBS) were retrieved. The total cost pre- and post-intensification of insulin was obtained from the pharmacy database. Differences in HbA1c, FBS and total insulin cost pre- and post-intensification were analysed.

Results: A total of 163 patients with T2DM who had intensification from human to analogue insulin were included in this study. HbA1c and FBS levels were significantly lower in analogue insulin. However, the differences were not clinically significant, as the mean reduction in HbA1c was less than 0.5%. Meanwhile, the total costs of analogue insulin for 3 months were higher.

Conclusion: There were no clinically significant improvements in patients' HbA1c and FBS after the intensification of insulin, despite the extra costs spent. Hence, it is vital to choose the right group of patients to receive an insulin analogue to maximise its benefit but at the most optimal cost.

References

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Palmer J, Gibbs M, Scheijbeler H, Kotchie R, Nielsen S, White J . Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther. 2008; 25(8):752-74. DOI: 10.1007/s12325-008-0080-4. View

Palmer J, Goodall G, Nielsen S, Kotchie R, Valentine W, Palmer A . Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. Curr Med Res Opin. 2008; 24(5):1417-28. DOI: 10.1185/030079908x297295. View

Singh S, Ahmad F, Lal A, Yu C, Bai Z, Bennett H . Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ. 2009; 180(4):385-97. PMC: 2638025. DOI: 10.1503/cmaj.081041. View

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B . Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010; 14(36):1-248. DOI: 10.3310/hta14360. View

Lee K, Seo S, Smith-Palmer J, Palmer J, White J, Valentine W . Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea. Value Health. 2010; 12 Suppl 3:S55-61. DOI: 10.1111/j.1524-4733.2009.00628.x. View

Ridderstrale M, Jensen M, Gjesing R, Niskanen L . Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden. J Med Econ. 2013; 16(4):468-78. DOI: 10.3111/13696998.2013.768999. View

Shafie A, Ng C . Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia. Clinicoecon Outcomes Res. 2020; 12:333-343. PMC: 7319511. DOI: 10.2147/CEOR.S244884. View

Tyndall V, Stimson R, Zammitt N, Ritchie S, McKnight J, Dover A . Marked improvement in HbA following commencement of flash glucose monitoring in people with type 1 diabetes. Diabetologia. 2019; 62(8):1349-1356. PMC: 6647076. DOI: 10.1007/s00125-019-4894-1. View

10.

Lage M, Boye K . The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes: evidence from a U.S. claims database. Curr Med Res Opin. 2020; 36(9):1441-1447. DOI: 10.1080/03007995.2020.1787971. View

11.

Valentine W, Palmer A, Erny-Albrecht K, Ray J, Cobden D, Foos V . Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. Adv Ther. 2006; 23(2):191-207. DOI: 10.1007/BF02850126. View

12.

Pratoomsoot C, Smith H, Kalsekar A, Boye K, Arellano J, Valentine W . An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK. Diabet Med. 2009; 26(8):803-14. PMC: 3228293. DOI: 10.1111/j.1464-5491.2009.02775.x. View

13.

Rys P, Pankiewicz O, Lach K, Kwaskowski A, Skrzekowska-Baran I, Malecki M . Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: a systematic review. Diabetes Metab. 2011; 37(3):190-200. DOI: 10.1016/j.diabet.2010.12.003. View

14.

Warren E, Weatherley-Jones E, Chilcott J, Beverley C . Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess. 2004; 8(45):iii, 1-57. DOI: 10.3310/hta8450. View

15.

Palmer J, Knudsen M, Aagren M, Thomsen T . Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting. J Med Econ. 2010; 13(2):212-20. DOI: 10.3111/13696991003723999. View

16.

Luo J, Khan N, Manetti T, Rose J, Kaloghlian A, Gadhe B . Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes. JAMA. 2019; 321(4):374-384. PMC: 6439763. DOI: 10.1001/jama.2018.21364. View

17.

Brandle M, Azoulay M, Greiner R . Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. Int J Clin Pharmacol Ther. 2011; 49(3):217-30. DOI: 10.5414/cpp49217. View

18.

Reviriego J, Gomis R, Maranes J, Ricart W, Hudson P, Sacristan J . Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia. Int J Clin Pract. 2008; 62(7):1026-32. PMC: 2438603. DOI: 10.1111/j.1742-1241.2008.01783.x. View

19.

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

20.

Colquitt J, Royle P, Waugh N . Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med. 2003; 20(10):863-6. DOI: 10.1046/j.1464-5491.2003.01018.x. View